Contact Allergy Cross-reactions and Thresholds

Dermatitis ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Andrew Scheman ◽  
Jenna L. Ruggiero ◽  
Lillian Kerchinsky ◽  
Jonathan H. Zippin ◽  
Matthew Zirwas ◽  
...  
1997 ◽  
Vol 8 (4) ◽  
pp. 231-235
Author(s):  
Raimo Suhonen ◽  
Lasse Kanerva

Dermatitis ◽  
2018 ◽  
Vol 29 (2) ◽  
pp. 91-92 ◽  
Author(s):  
Andrew Scheman ◽  
Ronald Te

Dermatitis ◽  
2017 ◽  
Vol 28 (4) ◽  
pp. 291 ◽  
Author(s):  
Andrew Scheman ◽  
Ronald Te

1981 ◽  
Vol 19 (2) ◽  
pp. 77-83 ◽  
Author(s):  
Toshio MATSUSHITA ◽  
Kohji AOYAMA

Dermatitis ◽  
2017 ◽  
Vol 28 (2) ◽  
pp. 128-140 ◽  
Author(s):  
Andrew Scheman ◽  
Ricky Hipolito ◽  
David Severson ◽  
Nineveh Youkhanis

Dermatitis ◽  
1997 ◽  
Vol 8 (4) ◽  
pp. 231-235
Author(s):  
Raimo Suhonen ◽  
Lasse Kanerva

1972 ◽  
Vol 106 (5) ◽  
pp. 715-716 ◽  
Author(s):  
G. A. Gellin
Keyword(s):  

Author(s):  
Gerhard Dobler

• TBE appears with non-characteristic clinical symptoms, which cannot be distinguished from oth-er forms of viral encephalitis or other diseases. • Cerebrospinal fluid and neuro-imaging may give some evidence of TBE, but ultimately cannot confirm the diagnosis. • Thus, proving the diagnosis “TBE” necessarily requires confirmation of TBEV-infection by detec-tion of the virus or by demonstration of specific antibodies from serum and/or cerebrospinal fluid. • During the phase of clinic symptoms from the CNS, the TBEV can only rarely be detected in the cerebrospinal fluid of patients. • Most routinely used serological tests for diagnosing TBE (ELISA, HI, IFA) show cross reactions resulting from either Infection with other flaviviruses or with other flavivirus vaccines.


Sign in / Sign up

Export Citation Format

Share Document